about
Opportunities for improving animal welfare in rodent models of epilepsy and seizuresSilencing Status Epilepticus-Induced BDNF Expression with Herpes Simplex Virus Type-1 Based Amplicon VectorsRisk of hospitalization for upper gastrointestinal tract bleedingAdvances in the development of biomarkers for epilepsy.Enhancement of GABA(A)-current run-down in the hippocampus occurs at the first spontaneous seizure in a model of temporal lobe epilepsy.Hippocampal FGF-2 and BDNF overexpression attenuates epileptogenesis-associated neuroinflammation and reduces spontaneous recurrent seizures.MicroRNA profiles in hippocampal granule cells and plasma of rats with pilocarpine-induced epilepsy--comparison with human epileptic samples.Systems genetics identifies Sestrin 3 as a regulator of a proconvulsant gene network in human epileptic hippocampus.Common data elements and data management: Remedy to cure underpowered preclinical studies.Circadian differences in the individual sensitivity to opiate overdose.Engineered HSV vector achieves safe long-term transgene expression in the central nervous system.Molecular analysis of behavior by gene transfer into neurons with herpes simplex vectors.Gene transfer into neurones for the molecular analysis of behaviour: focus on herpes simplex vectors.Preclinical evaluation of CHF3381 as a novel antiepileptic agent.WONOEP appraisal: new genetic approaches to study epilepsyIdentification of miRNAs differentially expressed in human epilepsy with or without granule cell pathology.Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist.Gene therapy for epilepsy.Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design.5-Hydroxytryptamine-mediated effects of nicotine on endogenous GABA efflux from guinea-pig cortical slicesChanges in [3H]-UK 14304 binding to alpha 2-adrenoceptors in morphine-dependent guinea-pigs.Targeting kinin receptors for the treatment of neurological diseases.WONOEP appraisal: Development of epilepsy biomarkers-What we can learn from our patients?Angels and demons: neurotrophic factors and epilepsy.Adenosine receptor antagonists alter the stability of human epileptic GABAA receptors.Issues for new antiepilepsy drug development.Implication of fibroblast growth factors in epileptogenesis-associated circuit rearrangements.The challenge and promise of anti-epileptic therapy development in animal models.Finding a better drug for epilepsy: antiepileptogenesis targets.Fgf-2 overexpression increases excitability and seizure susceptibility but decreases seizure-induced cell loss.Progress in gene therapy for neurological disorders.Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development.Unverricht-Lundborg disease.Effects of [Nphe1, Arg14, Lys15] N/OFQ-NH2 (UFP-101), a potent NOP receptor antagonist, on molecular, cellular and behavioural alterations associated with chronic mild stress.Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes.A pathogenetic hypothesis of temporal lobe epilepsy.Increased extracellular levels of glutamate in the hippocampus of chronically epileptic rats.The neurochemistry of morphine addiction in the neocortex.eIF4B phosphorylation at Ser504 links synaptic activity with protein translation in physiology and pathology.Impairment of GABA release in the hippocampus at the time of the first spontaneous seizure in the pilocarpine model of temporal lobe epilepsy.
P50
Q26786226-F5747904-9A72-4492-9C52-6626940EC99FQ27318403-6A59EE88-88C2-4381-99E7-2F300EBBA5E8Q28167756-01F6AE17-76C0-48C2-9860-BA412BE1C924Q30249613-9973ED29-587A-4BDC-AA3F-E6A40611C2ACQ30493725-E9AE1BEC-DCE4-47E9-8B9C-D0871258E3D8Q30497503-08CE3400-05FF-4AC4-9DE3-D09801449317Q30665824-EB523E97-3717-4EED-8302-4E083D843C35Q30671242-F07E6A25-6115-437C-84B8-E80CAB0E1753Q31152103-DAD94365-30D9-44A9-9A5E-16BD84A36B61Q31930309-13D2CA89-A504-477C-890B-FC2724B94A34Q33685490-A42FA631-570C-4987-8E42-357AB8767304Q33711544-E6280296-995D-4EBE-B8FF-96E62308E97FQ33899454-37EA397C-2BBE-4176-8681-394566C8C3E6Q33948643-BA6BE7E1-DAC1-4E8A-854C-ED02DFAD752CQ34021111-CB99AD14-75E5-4519-A43A-51F5C84BC749Q34078569-754FBCB5-0137-49E6-BABC-EAABD96E9443Q34159730-46DCDA6C-081B-42BD-8AC9-91290E303B53Q34375803-7F77CEAB-0448-46D8-BC73-9B020B1AE02CQ34400159-E1A9EFEF-AA27-4E50-8139-6580C578B8E0Q35873075-798D116A-53DA-4825-AFF6-C2657C4D4991Q35873153-3ED4B248-847C-4463-9E13-2FEC2F203AE0Q36107469-666136DE-0BDA-42E4-A8BE-694819189030Q36339575-D9D76E7A-6582-4554-84A7-8838B7ADB5CEQ36630307-E0273628-9FC1-47DC-987A-8D51766B5A3CQ36937193-951FB147-AF32-497E-805C-7302689833B8Q37164052-D17E822F-F5B6-41C7-B9EA-239732DE1C0BQ37168681-3D2EA08D-FA18-4DFF-ADDF-9D037441C1EEQ37214420-92EF23D2-829D-4C9C-9194-096139B7BD1FQ37232240-8376892D-626B-432E-9BC5-7A35EEB901A3Q37352269-D78B7E1C-F2DA-47B9-8D5C-893F201FDE81Q38100997-7A51AB0C-3FBF-40E1-B6C3-64B7DBB92073Q38126108-58B752CB-AD27-4BCC-935D-5874E24F2776Q38825684-6446DE80-F1FD-4BA0-8AED-91200A53D9FCQ38833155-83BEC2D7-592D-4AA4-8D9F-8D475F170D07Q40124870-5A174611-0155-4F80-9D80-12A3672D61FDQ40823685-C5834E71-DDD8-4693-81E0-C38E3A5619B2Q40836460-8BED6143-2A13-4018-9258-3CEBBA760382Q41304884-A04E1442-B40F-4A55-9BC6-058FED8DE103Q41620823-24FAD56B-8672-46A3-9A0F-3F5A246FA6F6Q42457999-5CB448FE-34C5-4353-9B14-2A9C359D7A04
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Michele Simonato
@ast
Michele Simonato
@en
Michele Simonato
@es
Michele Simonato
@nl
type
label
Michele Simonato
@ast
Michele Simonato
@en
Michele Simonato
@es
Michele Simonato
@nl
prefLabel
Michele Simonato
@ast
Michele Simonato
@en
Michele Simonato
@es
Michele Simonato
@nl
P106
P1153
7007172244
P31
P496
0000-0002-3586-2693